ALGS - Aligos Therapeutics Inc

https://www.aligos.com

Momentum: Bearish

Recent News

Sanofi Gets FDA Nod for Wayrilz in Immune Thrombocytopenia

Zacks Commentary • 1 week, 6 days ago • score: -0.07

SNY wins FDA approval for Wayrilz, the first BTK inhibitor for immune thrombocytopenia, with broader rare disease studies underway.

Neutral

Aligos Therapeutics, Inc. ( ALGS ) Reports Q2 Loss, Misses Revenue Estimates

Zacks Commentary • 1 month, 1 week ago • score: 0.07

Aligos Therapeutics (ALGS) delivered earnings and revenue surprises of +34.89% and -3.50%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Interval:

EMA1: EMA2:

AI Tools

Key Metrics

Trend: Downtrend

Source: Snapshot

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on developing novel therapies to address unmet medical needs in viral and liver diseases. The company is headquartered in South San Francisco, California.

52W High

$46.80

52W Low

$3.76

MA Status:

50D: Below 200D: Below

Beta (~1 neutral, <0.9 lower risk)

2.80

Valuation

As of 2025-06-30 (Overview)

Trailing P/E (<15 better)

N/A

Forward P/E (<15 better)

N/A

EV/EBITDA (<8 favorable)

0.58

EV/Revenue (<3 favorable)

0.38

P/S (TTM) (<3 favorable)

24.84

P/B (<3 favorable)

0.77

Ownership

Balanced

Source: Overview

Insiders (1–5% typical)

10.37%

Institutions (25–75% balanced)

54.15%

Shares Outstanding

6,151,400

Float

3,002,000

Dividend Yield (2–6% sweet spot)

N/A

Ex‑Dividend Date

N/A

Income & Growth

Profitability: Weak

As of 2025-06-30 (Overview)

Revenue (TTM)

3,174,000

Gross Profit (TTM)

-58,109,000

EPS (TTM)

-13.27

Profit Margin (>10% good)

N/A

Operating Margin (TTM) (higher better)

-19.24%

ROE (TTM) (>15% strong)

-0.88%

EPS YoY (Quarterly) (>10% good)

N/A

Revenue YoY (Quarterly) (>8% good)

-0.09

Momentum

Bearish momentum

Value

0.7945

0.8433

Trend

Falling

Signal Cross

No cross

As of

Sep. 11, 2025